The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...
The following is a summary of "Determining the Impact of COVID-19 Infection on Patients Hospitalized With COPD Exacerbations: ...
The following is a summary of “Losing Your Breath During the Storm: Spontaneous Pneumothorax and Subcutaneous Emphysema as a ...
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...
Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback